Market Overview:
The global neurothrombectomy devices market size reached US$ 695.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,123.0 Million by 2032, exhibiting a growth rate (CAGR) of 5.47% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 695.3 Million |
Market Forecast in 2032
|
US$ 1,123.0 Million |
Market Growth Rate 2024-2032 |
5.47% |
A neurothrombectomy is performed to retrieve or destroy blood clots in the cerebral neurovasculature using laser, mechanical and ultrasound technologies. It is primarily used for rapid achievement of recanalization, and increasing efficiency to treat large vessel occlusions and lowering the risk of hemorrhagic events. It also assists in minimizing the mortality rate among patients and improving functional outcomes. As a result, neurothrombectomy devices are extensively utilized in the treatment of acute ischemic stroke (AIS) across the globe.
According to the World Health Organization (WHO), stroke represents one of the leading causes of dementia and depression across the globe. It results in the sudden death of brain cells on account of the lack of oxygen. As neurothrombectomy devices aid in destroying blood clots, increasing blood supply to the brain and decreasing the mortality rate, the rising instances of AIS, particularly among the geriatric population, are positively influencing the growth of the market. Additionally, due to the rapid product approval process, leading manufacturers are introducing technologically advanced variants. For instance, Medtronic PLC launched its fourth-generation Solitaire X revascularization device in April 2019 for the treatment of AIS. This device features an optimized delivery system for improved efficiency while also retaining the technical features. Similarly, Vesalio obtained Conformite Europeenne (CE) mark approval for NeVa, an advanced neurothrombectomy device, in May 2019 and introduced an optimized delivery system for efficient results. This device relies on the DropZone and Smart Marker technology and features characteristics like a distal filter. Other factors, including the increasing adoption of unhealthy lifestyles and the escalating demand for minimally invasive surgeries by individuals, are anticipated to foster the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurothrombectomy devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and end use.
Breakup by Product:
- Clot Retrievers
- Aspiration/Suction Devices
- Vascular Snares
- Others
Breakup by End Use:
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Acandis GmbH, Shandong Weigao Group Medical Polymer Company Limited, Edwards Lifesciences Corporation, Johnson & Johnson, Koninklijke Philips N.V., Medtronic Plc, Penumbra Inc., Phenox GmbH, Stryker Corporation, Teleflex Incorporated, Terumo Corporation and Vesalio LLC.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Million |
Segment Coverage |
Product, End Use, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Acandis GmbH, Shandong Weigao Group Medical Polymer Company Limited, Edwards Lifesciences Corporation, Johnson & Johnson, Koninklijke Philips N.V., Medtronic Plc, Penumbra Inc., Phenox GmbH, Stryker Corporation, Teleflex Incorporated, Terumo Corporation and Vesalio LLC |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global neurothrombectomy devices market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global neurothrombectomy devices market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global neurothrombectomy devices market and who are the key players?
- What is the degree of competition in the industry?